Fears Of Congressional Revision Cloud Clinton Budget Prospects

Policy-watchers wonder if even modest increases for science will survive Republican lawmakers' fiscal conservatism The Clinton administration is striving to put the best possible "spin" on its $72.9 billion research and development budget for the 1996 fiscal year, which would provide modest increases--about enough to keep pace with inflation--for the National Science Foundation and the National Institutes of Health. White House science adviser John H. Gibbons contends that "science and technol

Written byBarton Reppert
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share


Policy-watchers wonder if even modest increases for science will survive Republican lawmakers' fiscal conservatism
The Clinton administration is striving to put the best possible "spin" on its $72.9 billion research and development budget for the 1996 fiscal year, which would provide modest increases--about enough to keep pace with inflation--for the National Science Foundation and the National Institutes of Health.

White House science adviser John H. Gibbons contends that "science and technology are maintained as a priority investment in the administration's FY96 budget submission, with total R&D funding increasing slightly, despite overall cuts in discretionary spending."

At the same time, however, science community observers and other Washington-based science policy-watchers say the administration's R&D budget faces highly uncertain prospects on Capitol Hill. With fiscally minded Republicans now in control of both the House and Senate, the final 1996 budget may bear little resemblance to the president's submission.

Cornelius J. Pings, president of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies